Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee reviews S154, which would direct cost study on insurance coverage for biomarker testing
Summary
The committee reviewed S154, which would direct DFR and AHS to analyze the costs to private insurance and Medicaid of requiring coverage for biomarker testing and report estimated premium and state fiscal impacts by Jan. 15, 2027.
The committee reviewed S154 on April 3, a bill that would require state agencies to estimate the fiscal effects if Vermont were to mandate insurance coverage for biomarker testing. Barbara Janke Harvey of the Office of Legislative Council summarized the bill’s definitions and reporting requirements.
Harvey said the bill defines a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses” and defines biomarker testing to include single‑analyte tests,…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
